Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when SNSE files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsSensei Biotherapeutics delays board appointment, sets five-director board size
Filed May 22, 2026 · Period ending May 22, 2026 · ~1 min read
Key Changes
-
low
Dr. Karen Vousden's board appointment postponed to Q3 or Q4 2026 due to personal reasons, delaying previously announced board reconstitution timeline.
Item 5.02 view on EDGAR → -
low
Board approved five-director size effective June 12, 2026, contingent on stockholder approval at June 10 Annual Meeting.
Item 5.02 view on EDGAR → -
low
Bob Holmen to chair Nominating and Corporate Governance Committee starting June 12, 2026, if stockholders approve required matters at Annual Meeting.
Item 5.02 view on EDGAR →
Summary
Sensei Biotherapeutics filed a routine governance update adjusting the timeline for its previously disclosed board reconstitution. Dr. Karen Vousden, who was expected to join the board following the company's June 10 Annual Meeting, has requested a delay until later in 2026 due to personal reasons. The board now plans to consider her appointment in the third or fourth quarter.
Meanwhile, the company is proceeding with other governance changes. Subject to stockholder approval at the upcoming Annual Meeting, Bob Holmen will become chair of the Nominating and Corporate Governance Committee on June 12, and the board will formally set its size at five directors. These are administrative adjustments to the board reconstitution plan already outlined in the company's proxy statement.
For retail investors, this filing has minimal immediate impact. The delay of one director appointment doesn't materially affect operations or strategy. Watch for the Annual Meeting results on June 10 to confirm whether stockholders approve the broader board changes, and monitor for Dr. Vousden's eventual appointment later this year.
Section-by-Section Diff
Event · Item 8.01 — Other Events
Item 8.01 — Other Events filed; see Key Changes for terms.
Show 3 minor / wording changes
Added in current filing · verify on EDGAR →
Due to personal reasons, Karen Vousden, Ph.D. has requested that her appointment to the Board be delayed until later in 2026. The Board intends to consider appointing Dr. Vousden in the third or fourth quarter of 2026.
Dr. Karen Vousden, who was expected to join the Board in connection with the June 10, 2026 Annual Meeting, has requested a delay due to personal reasons. The Board now plans to consider her appointment in Q3 or Q4 2026 instead.
Added in current filing · verify on EDGAR →
If the Required Company Stockholder Matters (as defined in the Definitive Proxy Statement) are approved at the Annual Meeting, the Board intends to appoint Bob Holmen as chair of the Nominating and Corporate Governance Committee, effective June 12, 2026, when the other board appointments described in the Definitive Proxy Statement would become effective.
Contingent on stockholder approval at the June 10 Annual Meeting, Bob Holmen will be appointed chair of the Nominating and Corporate Governance Committee effective June 12, 2026. This is part of the broader Board reconstitution described in the company's proxy statement.
Added in current filing · verify on EDGAR →
The Board has also approved a Board size of five directors as of that date.
The Board has approved reducing or setting its size to five directors effective June 12, 2026, coinciding with the other Board changes following the Annual Meeting.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · May 24, 2026 · How we verify